CD22 and non-Hodgkin lymphoma: Chimeric anti-CD22 SM03 was subjected to Phase I dose-escalation clinical studies in years 2007 to 2008 to evaluate its safety, pharmacokinetic properties and biological effect in Chinese non-Hodgkin lymphoma patients [13].